| Hospice Compassus-payson 511 South Mudspring Road, Suite #1, Payson, AZ, 85541 | |
| (928) 472-6340 |
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| Name | Hospice Compassus-payson |
|---|---|
| Location | 511 South Mudspring Road, Suite #1, Payson, Arizona |
| Hospice ID | 031523 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 030 |
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| NPI Number | 1568492395 |
| Organization Name | Rta Hospice, Inc. |
| Address | 511 S Mud Springs Road Payson, Arizona, 85541 |
| Phone Number | (928)472-6340 |
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.7 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 92.2 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 97.8 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 85.6 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 98.3 | 97.3 |
| Patients who got timely treatment for shortness of breath | 82.9 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| Home Health Aides | 12 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 2 |
| Medical Social Workers | 1.5 |
| Physicians | 2 |
| Registered Nurses | 16 |
| Other Personnel | 2 |
| Total Employees | 36.5 |
|---|
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| Others | 24 |
| Total Volunteers | 24 |
|---|
News Archive
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.
EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.
Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.
Ankush Gosain, MD, PhD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center has focused his research on determining the mechanisms underlying abnormal development of the enteric nervous system in Hirschsprung disease.
› Verified 3 days ago
| Hospice Compassus-payson Location: 511 South Mudspring Road, Suite #1, Payson, Arizona, 85541 Phone: (928) 472-6340 |
| Hospice Of Payson, Llc Location: 900 North Beeline Highway, Suite B, Payson, Arizona, 85541 Phone: (928) 472-6340 |